Helicobacter pylori in Bahrain: A Comprehensive Study of Patient Characteristics, Treatment Approaches, and Cure Rates

巴林幽门螺杆菌感染:患者特征、治疗方法和治愈率的综合研究

阅读:1

Abstract

Introduction Helicobacter pylori (H. pylori) bacteria is a major cause of gastritis, peptic ulcer disease, and functional dyspepsia. Although the treatment of H. pylori has evolved over time, challenges exist due to antibiotic resistance and variations in treatment outcomes. This study aimed to determine the characteristics and treatment outcomes of patients with H. pylori infection in Bahrain. Materials and methods A cross-sectional study of adults with H. pylori attending primary and secondary care settings was conducted. H. pylori was diagnosed based on the urea breath test. A computer-based simple random sample was obtained. Patients and treatment characteristics were determined from medical records. Descriptive and inferential analyses were conducted. Results A total of 709 patients were included, with an average age of 40.9±14.9 years. Nearly two-thirds of the participants were females (n=461, 65%) and diagnosed in primary care settings (n=464, 65.4%). Of the participants, 74.9% received treatment for H. pylori, with triple therapy (n=384, 72.3%) being the most used regimen in primary and secondary care hospitals, followed by the concomitant regimen (n=72, 13.6%). Bismuth-based quadruple therapy (P<0.001), concomitant therapy (P<0.001), and levofloxacin triple therapy (P=0.020) were used more frequently in secondary care settings compared to primary care settings. Nearly one-third of the patients underwent a test of cure (n=260, 36.7%). No significant association was found between the used regimen and the cure rate (P=0.938). Conclusion In summary, this study revealed comparable cure rates for H. pylori regardless of the antimicrobial regimens. Although most participants who underwent the test of cure had a negative test, the study highlighted the suboptimal management and follow-up of H. pylori cases. Prospective randomized controlled trials are needed to determine the exact effectiveness of each regimen among patients with H. pylori.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。